168 related articles for article (PubMed ID: 20351192)
1. Functional characterization of the recombinant human C1 inhibitor serpin domain: insights into heparin binding.
Rossi V; Bally I; Ancelet S; Xu Y; Frémeaux-Bacchi V; Vivès RR; Sadir R; Thielens N; Arlaud GJ
J Immunol; 2010 May; 184(9):4982-9. PubMed ID: 20351192
[TBL] [Abstract][Full Text] [Related]
2. Mapping the binding site of C1-inhibitor for polyanion cofactors.
Hor L; Pan J; Whisstock JC; Pike RN; Wijeyewickrema LC
Mol Immunol; 2020 Oct; 126():8-13. PubMed ID: 32717572
[TBL] [Abstract][Full Text] [Related]
3. Regulation of C1-inhibitor function by binding to type IV collagen and heparin.
Patston PA; Schapira M
Biochem Biophys Res Commun; 1997 Jan; 230(3):597-601. PubMed ID: 9015369
[TBL] [Abstract][Full Text] [Related]
4. Expression of active human C1 inhibitor serpin domain in Escherichia coli.
Lamark T; Ingebrigtsen M; Bjørnstad C; Melkko T; Mollnes TE; Nielsen EW
Protein Expr Purif; 2001 Jul; 22(2):349-58. PubMed ID: 11437612
[TBL] [Abstract][Full Text] [Related]
5. Structure and function of the serine-protease subcomponents of C1: protein engineering studies.
Gál P; Závodszky P
Immunobiology; 1998 Aug; 199(2):317-26. PubMed ID: 9777415
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1.
Murray-Rust TA; Kerr FK; Thomas AR; Wu T; Yongqing T; Ong PC; Quinsey NS; Whisstock JC; Wagenaar-Bos IC; Freeman C; Pike RN
Biochem J; 2009 Aug; 422(2):295-303. PubMed ID: 19522701
[TBL] [Abstract][Full Text] [Related]
7. The structure and function of the first component of complement: genetic engineering approach (a review).
Gál P; Cseh S; Schumaker VN; Závodszky P
Acta Microbiol Immunol Hung; 1994; 41(4):361-80. PubMed ID: 7866721
[TBL] [Abstract][Full Text] [Related]
8. Structure and function of C1 inhibitor.
Davis AE
Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and regulation of C1 inhibitor in human skin fibroblasts.
Katz Y; Strunk RC
J Immunol; 1989 Mar; 142(6):2041-5. PubMed ID: 2537870
[TBL] [Abstract][Full Text] [Related]
10. Antibody-independent C1 activation by E. coli.
Tenner AJ; Ziccardi RJ; Cooper NR
J Immunol; 1984 Aug; 133(2):886-91. PubMed ID: 6376630
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional structure and molecular modelling of C1- inhibitor.
Perkins SJ
Behring Inst Mitt; 1993 Dec; (93):63-80. PubMed ID: 8172587
[TBL] [Abstract][Full Text] [Related]
12. C1 dissociation. Spontaneous generation in human serum of a trimer complex containing C1 inactivator, activated C1r, and zymogen C1s.
Laurell AB; Mårtensson U; Sjöholm AG
J Immunol; 1987 Dec; 139(12):4145-51. PubMed ID: 2826582
[TBL] [Abstract][Full Text] [Related]
13. C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation.
Beinrohr L; Dobó J; Závodszky P; Gál P
Trends Mol Med; 2008 Dec; 14(12):511-21. PubMed ID: 18977695
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of the serpin domain of C1 inhibitor.
Coutinho M; Aulak KS; Davis AE
J Immunol; 1994 Oct; 153(8):3648-54. PubMed ID: 7930585
[TBL] [Abstract][Full Text] [Related]
15. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1.
Kirschfink M; Blase L; Engelmann S; Schwartz-Albiez R
J Immunol; 1997 Feb; 158(3):1324-31. PubMed ID: 9013976
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor.
Kerr FK; Thomas AR; Wijeyewickrema LC; Whisstock JC; Boyd SE; Kaiserman D; Matthews AY; Bird PI; Thielens NM; Rossi V; Pike RN
Mol Immunol; 2008 Feb; 45(3):670-7. PubMed ID: 17709141
[TBL] [Abstract][Full Text] [Related]
17. C1 subcomponent complexes: basic and clinical aspects.
Laurell AB; Sjöholm AG
Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
[TBL] [Abstract][Full Text] [Related]
18. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
[TBL] [Abstract][Full Text] [Related]
19. alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
Sulikowski T; Bauer BA; Patston PA
Protein Sci; 2002 Sep; 11(9):2230-6. PubMed ID: 12192078
[TBL] [Abstract][Full Text] [Related]
20. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
